New fibrate use and acute renal outcomes in elderly adults a population-based study

Annals of Internal Medicine

Volumn 156, Issue 8, 2012, Pages 560-569

  Zhao, Ying Y ^a   Weir, Matthew A ^a   Manno, Michael ^a   Cordy, Peter ^a   Gomes, Tara ^a   Hackam, Daniel G ^a   Juurlink, David N ^a   Mamdani, Muhammad ^a   Moist, Louise ^a   Parikh, Chirag R ^a   Michael Paterson, J ^a   Wald, Ron ^a   Yao, Zhan ^a   Garg, Amit X ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CANADA; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONSULTATION; CREATININE BLOOD LEVEL; DRUG USE; DYSLIPIDEMIA; ELDERLY CARE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MORTALITY; OUTCOME ASSESSMENT; OUTPATIENT CARE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SIDE EFFECT;

EID: 84859773995     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-8-201204170-00401     Document Type: Article

References (54)

1. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25:567-79.[PMID: 19812802]
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39.[PMID: 15249516]
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al; American Heart Association. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.[PMID: 16157765]
4. Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. Am J Kidney Dis. 2004;44:543-50.[PMID: 15332227]
5. Ansquer JC, Dalton RN, Causse ́ E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904-13.[PMID: 18501783]
6. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000;15:1993-9.[PMID: 11096145]
7. Bruce R, Daniels A, Cundy T. Renal function changes in diabetic nephrop-athy induced by bezafibrate [Letter]. Nephron. 1996;73:490.[PMID: 8832617]
8. Gajdos M, Dzúrik R. Fibrates and renal function [Letter]. Clin Nephrol. 2003;60:65-6.[PMID: 12872864]
9. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A. Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency. Nephrologie. 1999;20:41-4.[PMID: 10081035]
10. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92:536-41.[PMID: 12372935]
11. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55:39-44.[PMID: 11200866]
12. McQuade CR, Griego J, Anderson J, Pai AB. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65:138-41. [PMID: 18192258]
13. Ritter JL, Nabulsi S. Fenofibrate-Induced elevation in serum creatinine. Pharmacotherapy. 2001;21:1145-9.[PMID: 11560205]
14. Genest J, Frohlich J, Steiner G. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. Am J Cardiol. 2004;93:848-53.[PMID: 15050487]
15. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74.[PMID: 20228404]
16. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61.[PMID: 16310551]
17. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325:1139.[PMID: 12433762]
18. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44:832-9.[PMID: 15492949]
19. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther. 2002;7:219-26.[PMID: 12490967]
20. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al; Fenofibrate Intervention and Event Lowering in Diabetes Study investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. 2011;54:280-90.[PMID: 21052978]
21. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-84.[PMID: 16985230]
22. Statistics Canada. Population by sex and age group, by province and territory. Ottawa: Statistics Canada; 2010. Accessed at http://www40.statcan.gc.ca /l01/cst01/demo31a-eng.htm on 23 April 2010.
23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenb-roucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344-9.[PMID: 18313558]
24. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67-71.[PMID: 12879144]
25. Alter DA, Naylor CD, Austin P, Tu JV. Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med. 1999;341:1359-67.[PMID: 10536129]
26. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study [Letter]. JAMA. 2003;289:3241-2.[PMID: 12824204]
27. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-8.[PMID: 12672733]
28. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-51.[PMID: 15295047]
29. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-6.[PMID: 15172772]
30. Mamdani MM, Tu JV. Did the major clinical trials of statins affect prescribing behaviour? [Letter]. CMAJ. 2001;164:1695-6.[PMID: 11450211]
31. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168:553-7.[PMID: 12615747]
32. Merck Canada Inc. Ezetrol Product Monograph. Kirkland, Quebec, Canada: Merck Canada Inc.; 2011. Accessed at www.merck.ca/assets/en/pdf/products /EZETROL-PM_E.pdf on 26 February 2012.
33. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-12.[PMID: 15312219]
34. Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228-34.
35. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330:960-2.[PMID: 15845982]
36. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-64.[PMID: 11682368]
37. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.[PMID: 10075613]
38. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.[PMID: 17331245]
39. Sica DA. Fibrate therapy and renal function. Curr Atheroscler Rep. 2009;11: 338-42.[PMID: 19664376]
40. Charach G, Grosskopf I, Rotmensch HH, Kitzis I, Weintraub M. Bezafi-brates cause moderate, reversible impairment in renal function in patients without prior renal disease. Nephron Clin Pract. 2005;100:c120-5.[PMID: 15849478]
41. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC; Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66:1123-30.[PMID: 15327407]
42. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005;45:485-93.[PMID: 15754270]
43. Smulders YM, van Eeden AE, Stehouwer CD, Weijers RN, Slaats EH, Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of mi-croalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest. 1997;27:997-1002.[PMID: 9466127]
44. Kazumi T, Hirano T, Yoshino G. Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study. Curr Ther Res Clin Exp. 2003;64:434-46.
45. U.S. Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee Meeting: Clinical Briefing Document. Washington, DC: U.S. Food and Drug Administration; 2011. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm277649.pdf on 26 February 2012.
46. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33:215-20.[PMID: 19846798]
47. Waikar SS, Wald R, Chertow GM, Curhan GC, Winkelmayer WC, Lian-gos O, et al. Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. J Am Soc Nephrol. 2006; 17:1688-94.[PMID: 16641149]
48. Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, et al; ACCORD Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-44.[PMID: 20587587]
49. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370:1687-97.[PMID: 17988728]
50. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122:962.e1-8.[PMID: 19698935]
51. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375:1875-84.[PMID: 20462635]
52. Juurlink DN, Prevra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information Discharge Abstract Database: A Val-dation Study. Toronto: Institute for Clinical Evaluative Sciences; 2006.
53. Jha P, Deboer D, Sykora K, Naylor CD. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol. 1996;27:1335-42.[PMID: 8626941]
54. Meade TW; For the British Medical Research Council General Practice Research Framework and participating vascular clinics. Design and intermediate esults of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN4119421]. Curr Control Trials Cardiovasc Med. 2001;2:195-204.[PMID: 11806795]